Illumina has entered into a definitive agreement to acquire proteomics leader SomaLogic from Standard BioTools for up to $425 million, strengthening its multiomics strategy. The purchase includes SomaLogic’s protein analysis platforms and a CLIA-certified facility in Boulder, Colorado. This deal builds on a multi-year collaboration aimed at integrating SomaLogic’s aptamer-based proteomics technology with Illumina’s next-generation sequencing systems. Illumina anticipates broadening advanced biomarker discovery and disease profiling capabilities, reinforcing its position in the growing proteomics market and accelerating commercial adoption of its Protein Prep assay solution.